NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November

About this update from Newamsterdam Pharma Company N.v.

NAARDEN, The Netherlands and MIAMI , Oct. 30, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present additional safety and efficacy data from the pivotal Phase 3 BROOKLYN, BROADWAY and TANDEM trials at the 2025 American Heart Association (AHA) Scientific Sessions, taking place November 7 – 10, 2025 in New Orleans, Louisiana . Additionally, NewAmsterdam announced that company management will participate in three upcoming investor conferences. Details are as follows: AHA Scientific Sessions 2025 Presentation Title: Cholesteryl Ester Transfer Protein (CETP) Inhibition with Obicetrapib Produces Substantial Reductions in LDL Particles: Pooled Analysis of BROOKLYN and BROADWAY Phase 3 Clinical Trials Session Title: Lipid Lowering Therapies and Lipid Risk Factors Oral Presentation Date and Time: Sunday, November 9, 2025 at 10:15am CT Presenter: John Kastelein Presentation Title: Obicetrapib in combination with ezetimibe on top of atorvastatin regresses atherosclerotic plaque lesions in APOE*3-Leiden.CETP mice Session Title: New Mechanisms to Control Hypercholesterolemia Digital Poster Presentation Date and Time: Monday, November 10, 2025 at 10:59am CT Presenter: Jose Inia Guggenheim 2 nd Annual Healthcare Innovation Conference Fireside Chat Date and Time: Tuesday, November 11, 2025 at 10:30am ET in Boston, MA Presenters: Michael Davidson , M.D., Chief Executive Officer, and Ian Somaiya , Chief Financial Officer Stifel Healthcare Conference Fireside Chat Date and Time: Wednesday, November 12, 2025 at 8:00am ET in New York, NY Presenters: Michael Davidson , M.D., Chief Executive Officer, and Ian Somaiya , Chief Financial Officer Jefferies London Healthcare Conference Fireside Chat Date and Time: Wednesday, November 19, 2025 at 5:00pm GMT Presenters: Ian Somaiya , Chief Financial Officer, and John Kastelein , M.D., Ph.D., FESC, Founder and Chief Scientific Officer Live webcasts of the fireside chats will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com . Following the live webcasts, archived replays will be available on the Company’s website. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company Contact Matthew Philippe P: 1-917-882-7512 [email protected] Media Contact Real Chemistry on behalf of NewAmsterdam Christian Edgington P: 1-513-310-6410 [email protected] Investor Contact Precision AQ on behalf of NewAmsterdam Austin Murtagh P: 1-212-698-8696 [email protected] Source: NewAmsterdam Pharma N.V.

View stock analysis, news, and events for Newamsterdam Pharma Company N.v.